UPDATE: Second drug gets UK early access scheme nod
This article was originally published in SRA
Executive Summary
In what appears to be just the second such decision by the UK regulator, the MHRA, Bristol-Myers Squibb's advanced melanoma product Opdivo (nivolumab) has been given the go-ahead to enter the early access to medicines scheme (EAMS), meaning it can be made available to patients in the UK advance of its eventual EU approval1.